Single-cell profiling guided combination therapy of c-Fos and histone deacetylase inhibitors in diffuse large B-cell lymphoma
Kramer, O. H., and Schneider, G. (2022). Clin Transl Med 12, e858. doi: 10.1002/ctm2.858
In this commentary on Wang, Wu, Xia, and colleagues, Clinical Translational Medicine, 2022, we sum up and discuss recent evidence on the regulation and relevance of the transcription factor c-FOS in diffuse large B cell lymphoma cells that are treated with epigenetic erasers of the histone deacetylase inhibitor family.